Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases
There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited respon...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
European respiratory review
Year: 2018, Jahrgang: 27, Heft: 150, Pages: 1-6 |
| ISSN: | 1600-0617 |
| DOI: | 10.1183/16000617.0078-2018 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1183/16000617.0078-2018 Verlag, Volltext: https://err.ersjournals.com/content/27/150/180078 
|
| Verfasserangaben: | Colin Holtze, Kevin Flaherty, Michael Kreuter, Fabrizio Luppi, Teng Moua, Carlo Vancheri and Mary B. Scholand |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1682132498 | ||
| 003 | DE-627 | ||
| 005 | 20230508162433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191119s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/16000617.0078-2018 |2 doi | |
| 035 | |a (DE-627)1682132498 | ||
| 035 | |a (DE-599)KXP1682132498 | ||
| 035 | |a (OCoLC)1341278376 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Holtze, Colin |e VerfasserIn |0 (DE-588)1199981486 |0 (DE-627)1682130703 |4 aut | |
| 245 | 1 | 0 | |a Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases |c Colin Holtze, Kevin Flaherty, Michael Kreuter, Fabrizio Luppi, Teng Moua, Carlo Vancheri and Mary B. Scholand |
| 264 | 1 | |c 2018 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.11.2019 | ||
| 520 | |a There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation. - Tweetable abstract ERSpublications - click to tweetData for ILDs with a progressive fibrosing phenotype are lacking, but the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF http://ow.ly/Eoht30mS4Nx | ||
| 700 | 1 | |a Flaherty, Kevin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 700 | 1 | |a Luppi, Fabrizio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moua, Teng |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vancheri, Carlo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scholand, Mary B. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European respiratory review |d Sheffield : Soc., 2005 |g 27(2018), 150, Artikel-ID 180078, Seite 1-6 |h Online-Ressource |w (DE-627)500021430 |w (DE-600)2202947-3 |w (DE-576)281286477 |x 1600-0617 |7 nnas |a Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases |
| 773 | 1 | 8 | |g volume:27 |g year:2018 |g number:150 |g elocationid:180078 |g pages:1-6 |g extent:6 |a Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases |
| 856 | 4 | 0 | |u https://doi.org/10.1183/16000617.0078-2018 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://err.ersjournals.com/content/27/150/180078 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191119 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1682132498 |e 3542417440 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Holtze","display":"Holtze, Colin","given":"Colin","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Flaherty, Kevin","roleDisplay":"VerfasserIn","role":"aut","given":"Kevin","family":"Flaherty"},{"family":"Kreuter","given":"Michael","roleDisplay":"VerfasserIn","role":"aut","display":"Kreuter, Michael"},{"display":"Luppi, Fabrizio","given":"Fabrizio","roleDisplay":"VerfasserIn","role":"aut","family":"Luppi"},{"family":"Moua","display":"Moua, Teng","roleDisplay":"VerfasserIn","role":"aut","given":"Teng"},{"display":"Vancheri, Carlo","role":"aut","roleDisplay":"VerfasserIn","given":"Carlo","family":"Vancheri"},{"display":"Scholand, Mary B.","roleDisplay":"VerfasserIn","role":"aut","given":"Mary B.","family":"Scholand"}],"relHost":[{"title":[{"title":"European respiratory review","title_sort":"European respiratory review"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"2005","publisherPlace":"Sheffield","dateIssuedDisp":"2005-","publisher":"Soc."}],"name":{"displayForm":["European Respiratory Society"]},"language":["eng"],"disp":"Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseasesEuropean respiratory review","recId":"500021430","part":{"volume":"27","issue":"150","text":"27(2018), 150, Artikel-ID 180078, Seite 1-6","extent":"6","year":"2018","pages":"1-6"},"note":["Gesehen am 31.10.24"],"pubHistory":["Nachgewiesen 14.2005 - ; auch mit durchgehender Nr.-Zählung"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["500021430"],"zdb":["2202947-3"],"issn":["1600-0617"]},"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"European Respiratory Society"}]}],"name":{"displayForm":["Colin Holtze, Kevin Flaherty, Michael Kreuter, Fabrizio Luppi, Teng Moua, Carlo Vancheri and Mary B. Scholand"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"id":{"doi":["10.1183/16000617.0078-2018"],"eki":["1682132498"]},"physDesc":[{"extent":"6 S."}],"title":[{"title":"Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases","title_sort":"Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1682132498","note":["Gesehen am 19.11.2019"]} | ||
| SRT | |a HOLTZECOLIHEALTHCARE2018 | ||